Across TCGA pan-cancer cohorts, IRAK4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IRAK4 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher IRAK4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IRAK4 expression acts as an unfavorable survival marker.

UCS and ESCA are the cancer types where IRAK4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	All	0.136	0.523	.034	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: IRAK4 tumor-vs-normal RNA expression · all IRAK4 data types